Mar. 12, 2026 at 9:07pm
Got story updates? Submit your updates here. ›
Cassava Sciences (NASDAQ:SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease treatments, reported its first quarter earnings results on Thursday. The company posted a loss of $0.26 per share, beating the consensus estimate of a $0.30 per share loss.
Why it matters
Cassava Sciences is developing a novel therapy for Alzheimer’s disease, a critical area of unmet medical need. The company’s ability to meet or exceed earnings expectations is an important signal about the progress of its drug development pipeline and financial health.
The details
Cassava Sciences reported a loss of $0.26 per share for the quarter, topping the average analyst estimate of a $0.30 per share loss. The company is currently focused on advancing its lead drug candidate, simufilam, which aims to restore normal function to a key scaffolding protein implicated in Alzheimer’s disease.
Cassava Sciences reported its Q1 2026 earnings results on Thursday, March 12, 2026.
The players
Cassava Sciences
A clinical-stage biopharmaceutical company focused on developing novel therapies and diagnostics for Alzheimer’s disease and related neurodegenerative disorders. The company is headquartered in Austin, Texas.
Got photos? Submit your photos here. ›
The takeaway
Cassava Sciences’ ability to exceed earnings expectations is an encouraging sign for the progress of its Alzheimer’s drug pipeline, which represents a critical area of unmet medical need. Investors will be closely watching the company’s continued development of its lead candidate, simufilam, as it advances through clinical trials.